Scientists from Memorial Sloan-Kettering have collaborated on the discovery of a unique monoclonal antibody, called ESK1, that appears to be effective at targeting and destroying several types of cancer cells.

Dr. Parra, who practices at Memorial Sloan-Kettering Basking Ridge, treats prostate, kidney, and bladder cancers with the goal of extending the lives of patients, and giving them the best possible quality of life.

At the seventh annual seminar for high school students and teachers, investigators discuss how cutting-edge biomedical research may ultimately contribute to better treatments for cancer patients.

Our doctors introduce and apply advanced technologies in minimal-access surgery to benefit patients.

Co-host Robin Roberts gives thanks to her Memorial Sloan-Kettering treatment team during her first day returning to the show after receiving a stem cell transplant.

Researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease.

Medical oncologist Mark Kris discusses how cancer experts are working to train IBM Watson to help assist medical professionals.